----item----
version: 1
id: {59AD74A7-22B6-42E0-82EA-2ABE8A3A691D}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/02/13/US quarterly results roundup
parent: {D00C9D21-A785-4CE1-B91B-2699D9C8D822}
name: US quarterly results roundup
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: 86677889-70fb-4977-8e5f-6c07f32ecf74

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 3

<p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 29

US quarterly results round-up
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1458

<p><pre>Everest Medical Revenues Net income (loss) ($ millions) ($ millions) 1994 1993 1994 1993 3 months 1.22 0.84 0.01 (0.37) Year 4.52 2.78 (0.79) (3.00) (ended Dec 31st)</pre><p>Everest, a manufacturer of bipolar electrosurgical instruments for MIS markets, linked up with Japanese medical device company KK Adachi in the fourth quarter to develop a new product for the Japanese market. Meanwhile, Everest introduced BiLAP, its needle electrode, and BiCOAG, its dissecting forceps, and began limited shipments of Evershears II metal-on-metal bipolar scissors.</p><pre>Corvita Revenues Net income (loss) ($ millions) ($ millions) 1994 1993 1994 1993 3 months 0.33 0.24 (1.45) (1.64) 6 months 0.51 0.41 (3.07) (3.32) (ended Dec 31st)</pre><p>Florida-based Corvita says most of its activities in fiscal 1995 will be focused on the development and testing of three different types of its endoluminal grafts for vascular trauma, vascular occlusive disease and aneurysmal disease.</p><pre>TheraTech Revenues Net loss ($ millions) ($ millions) 1994 1993 1994 1993 3 months 4.22 0.85 (2.13) (4.50) Year 7.54 5.47 (11.64) (7.87) (ended Dec 31st)</pre><p>TheraTech's filing of an NDA for its testosterone <strong>[C#199901331:transdermal]</strong> patch (see Clinica No 634, p 22) resulted in increased R&D spending in 1994. After a public stock offering in February, TheraTech ended 1994 with $29 million in cash, more than $10 million up from a year earlier.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 155

{B2967A9C-ABDA-4628-A672-9EDDCD142AEA}|{FC1DA89F-D8A0-415D-99B6-86FF397EC709}|{2E0CEEF8-031D-43E8-B6AA-07D1397D9E4F}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 28

US quarterly results roundup
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950213T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950213T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950213T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT051461
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 29

US quarterly results round-up
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

199901331
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

253241
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T183848Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

86677889-70fb-4977-8e5f-6c07f32ecf74
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T183850Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
